- Home
- CSTL vs TROX Comparison
CSTL vs TROX Comparison
Compare CSTL & TROX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- TROX
- Stock Information
- Founded
- CSTL 2007
- TROX 2018
- Country
- CSTL United States
- TROX United States
- Employees
- CSTL N/A
- TROX N/A
- Industry
- CSTL Medical Specialities
- TROX Major Chemicals
- Sector
- CSTL Health Care
- TROX Industrials
- Exchange
- CSTL Nasdaq
- TROX Nasdaq
- Market Cap
- CSTL 661.7M
- TROX 640.4M
- IPO Year
- CSTL 2019
- TROX 2005
- Fundamental
- Price
- CSTL $22.14
- TROX $3.54
- Analyst Decision
- CSTL Strong Buy
- TROX Hold
- Analyst Count
- CSTL 6
- TROX 8
- Target Price
- CSTL $37.67
- TROX $4.70
- AVG Volume (30 Days)
- CSTL 296.4K
- TROX 4.5M
- Earning Date
- CSTL 11-03-2025
- TROX 11-05-2025
- Dividend Yield
- CSTL N/A
- TROX 5.69%
- EPS Growth
- CSTL N/A
- TROX N/A
- EPS
- CSTL N/A
- TROX N/A
- Revenue
- CSTL $346,269,000.00
- TROX $2,949,000,000.00
- Revenue This Year
- CSTL N/A
- TROX N/A
- Revenue Next Year
- CSTL N/A
- TROX $3.93
- P/E Ratio
- CSTL N/A
- TROX N/A
- Revenue Growth
- CSTL 20.40
- TROX 0.24
- 52 Week Low
- CSTL $14.59
- TROX $2.95
- 52 Week High
- CSTL $35.84
- TROX $14.93
- Technical
- Relative Strength Index (RSI)
- CSTL 46.56
- TROX 40.70
- Support Level
- CSTL $22.16
- TROX $3.32
- Resistance Level
- CSTL $23.19
- TROX $4.29
- Average True Range (ATR)
- CSTL 0.89
- TROX 0.29
- MACD
- CSTL -0.16
- TROX -0.02
- Stochastic Oscillator
- CSTL 10.05
- TROX 22.16
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About TROX Tronox Holdings plc (UK)
Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.